In CAP requiring hospitalization with concern for MRSA, which drug is an option to add?

In CAP requiring hospitalization with concern for MRSA, which drug is an option to add?

• A. Vancomycin
• B. Linezolid
• C. Doxycycline
• D. Ceftriaxone

Answer: (B)

When managing community-acquired pneumonia that’s severe enough to require hospitalization and there’s concern for MRSA, you add coverage specifically aimed at MRSA. Linezolid is a strong option here because it directly targets MRSA and has pharmacologic advantages for pneumonia. Linezolid delivers excellent activity against MRSA isolates, including strains common in hospital and community settings, and it achieves high concentrations in lung tissue and the epithelial lining fluid where the infection sits. It can be given intravenously or switched to an oral form, which makes it convenient for stepping down therapy once the patient improves. Compared with vancomycin, linezolid tends to provide more reliable lung penetration and does not require trough-level monitoring for dose optimization, and it isn’t nephrotoxic like vancomycin can be. Doxycycline and ceftriaxone don’t reliably cover MRSA in this setting, so they’re less suitable when MRSA is a concern. Vancomycin is a valid MRSA option, but linezolid often offers practical and pharmacokinetic advantages in pneumonia management, making it the preferred choice among these options.

When managing community-acquired pneumonia that’s severe enough to require hospitalization and there’s concern for MRSA, you add coverage specifically aimed at MRSA. Linezolid is a strong option here because it directly targets MRSA and has pharmacologic advantages for pneumonia.

Linezolid delivers excellent activity against MRSA isolates, including strains common in hospital and community settings, and it achieves high concentrations in lung tissue and the epithelial lining fluid where the infection sits. It can be given intravenously or switched to an oral form, which makes it convenient for stepping down therapy once the patient improves. Compared with vancomycin, linezolid tends to provide more reliable lung penetration and does not require trough-level monitoring for dose optimization, and it isn’t nephrotoxic like vancomycin can be.

Doxycycline and ceftriaxone don’t reliably cover MRSA in this setting, so they’re less suitable when MRSA is a concern. Vancomycin is a valid MRSA option, but linezolid often offers practical and pharmacokinetic advantages in pneumonia management, making it the preferred choice among these options.